Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 16/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14488121 | 0.94 | PDE2A (0.50) | PDE2APDE3APDE3B | |
| SCHEMBL16011360 | 0.94 | PDE2A (0.50) | PDE2APDE3APDE3B | |
| SCHEMBL5128661 | 0.93 | CSNK2A2 (0.40) | PDE2APDE3APDE3BCSNK2A2CSNK2A1 | |
| SCHEMBL5077314 | 0.91 | PDE2A (0.44) | PDE2APDE3APDE3BCSNK2A2CSNK2A1 | |
| SCHEMBL19377763 | 0.84 | TYRO3 (0.45) | PDE2APDE3ACSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL5080202 | 0.84 | DOT1L (0.38) | PDE2APDE3APDE3BCSNK2A2CSNK2A1 | |
| SCHEMBL64853 | 0.83 | RIPK1 (0.46) | PIK3CD | |
| SCHEMBL22132928 | 0.81 | RIPK1 (0.39) | PDE2APDE3APDE3BCSNK2A2CSNK2A1 | |
| SCHEMBL5080389 | 0.79 | CSNK2A2 (0.35) | PDE2APDE3APDE3BCSNK2A2CSNK2A1 | |
| SCHEMBL5141366 | 0.79 | PIK3CD (0.44) | PDE2ACSNK2A2CSNK2A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | PDE2A 2382/4885PDE3A 2772/4885PDE3B 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.